Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Rheumatology International

Volumn 27, Issue 6, 2007, Pages 531-536

  Sánchez, Gloris ^a   Castro, Julio S ^b   Snih, Soham Al ^c   Blanco, Luísa Pérez ^a   Esteva, María H ^a   MacGregor, Ernesto García ^a   González, Marielena ^a   Granados, Ysabel ^a   Marín, Francisco ^a   Rosas, Alexis ^a   Tristano, Antonio ^a   Chirinos, Esther ^a   Mundaraín, Luís ^a   Sanoja, Gilberto ^a   Zambrano Marín, Guisela ^a   Rodríguez, Martín A ^a,d  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d NONE   (Venezuela)

Author keywords

Latin America; Methotrexate; Rheumatoid arthritis; Tolerability

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GOLD SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CONTROLLED STUDY; COUGHING; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HISPANIC; HUMAN; HYPERPIGMENTATION; KAPLAN MEIER METHOD; LEUKOPENIA; LIFE TABLE METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PRURITUS; RASH; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SKIN BRUISING; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; VENEZUELA; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; KAPLAN-MEIERS ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VENEZUELA;

EID: 33947145285     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0261-x     Document Type: Article

References (30)

1. Weinblatt ME, Cobby JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822
2. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuck KR, et al (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 35:129-137
3. Tugwell P, Bennet K, Gent M (1987) Methotrexate in rheumatoid arthritis. Ann Intern Med 107:358-366
4. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, Box JH, et al (1992) Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 35:849-856
5. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492-1428
6. Thompson RN, Watts C, Edeelman J, Esdaile J, Russell AS (1984) A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11:760-762
7. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis-a controlled clinical trial. Arthritis Rheum 28:721-729
8. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatism arthritis. Arthritis Rheum 31:315-324
9. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheumatism 35:498-502
10. Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662
11. O'Dell JR (1997) Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 23:779-796
12. Pincus T, Marcum SB, Callahan LF (1992) Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 19:1885-1894
13. Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 40:984
14. Wolfe F (1995) The epidemiology of drug treatment failure in rheumatoid arthritis. Clin Rheumatol 9:619-632
15. Cronstein BN (2004) Pharmacogenetics in the rheumatic diseases. Ann Rheum Dis 63(Suppl II):ii25-ii27
16. Alarcon GS, Tracy IC, Blackburn WD (1989) Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32:671-676
17. Kremer JM, Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29:822-831
18. Rau R, Schleusser B, Herborn G, Karger T (1998) Longterm combination therapy for refractory and destructive rheumatoid arthritis with mehotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to methotrexate monotherapy. J Rheumatol 25:1485-1492
19. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open long-term study of 191 cases. J Rheumatol 18:1323-1327
20. Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of tradional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62:482-486
21. Goodman TA, Polisson RP (1994) Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 20:513-528
22. van Ede AE, Laan RFJM, Blom HJ, De Abreu RA, van de Putte LBA (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 28:277-292
23. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44:61-66
24. O'Dell JR (2004) Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350:2591-2602
25. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al (1999) Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220-225
26. Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D (1997) Toxicity profile of dual methotrexate combinations with gold, hydroxichloroquine, sulphasalazine and minocycline in rheumatoid arthritis. Rheumatol Int 17:49-53
27. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatol 39:975-981
28. Fox RI (1998) Mechanism of action of Leflunomide in rheumatoid arthritis. J Rheumatol 53(Suppl 25):20-26
29. Segal R, Yaaron M, Tartakovsky B (1990) Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 20:190-199
30. Kremer JL (1999) Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:14-26